Cost-cutting helps Cyberonics shrink quarter 1 loss
This article was originally published in Clinica
Cyberonics narrowed its net loss for the first quarter of fiscal 2008, as the company's cost-savings initiatives - implemented during the quarter - begin to take effect.
You may also be interested in...
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
Results of a forthcoming APhA survey showed about one-third cannot store Pfizer/BioNTech's BNT162b2, but can handle Moderna's mRNA-1273.